Conexeu Sciences Inc. (NASDAQ:CNXU – Get Free Report) Director Lynn Sebastian Purcell bought 202,500 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were bought at an average cost of $0.80 per share, with a total value of $162,000.00. Following the transaction, the director directly owned 2,734,240 shares of the company’s stock, valued at approximately $2,187,392. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Conexeu Sciences Stock Performance
Shares of CNXU stock opened at $10.22 on Friday. Conexeu Sciences Inc. has a 12 month low of $9.60 and a 12 month high of $18.79.
Wall Street Analyst Weigh In
CNXU has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. HC Wainwright started coverage on shares of Conexeu Sciences in a report on Monday. They set a “buy” rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $20.00.
About Conexeu Sciences
Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.
Featured Stories
- Five stocks we like better than Conexeu Sciences
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Conexeu Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conexeu Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
